Scarica l'app Stockscreener
23.74
0.38%
0.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts? - Yahoo Finance
Structure Therapeutics’ (GPCR) “Buy” Rating Reiterated at HC Wainwright - Defense World
Daily Progress: Structure Therapeutics Inc ADR (GPCR) Drop -11.51, Closing at 21.03 - DWinneX
Metric Analysis: Silvercorp Metals Inc (SVM)’s Key Ratios in the Limelight - DWinneX
Ratios Revealed: Decoding Structure Therapeutics Inc ADR (GPCR)’s Financial Health - DWinneX
Invesco Ltd. Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
A Guide To The Risks Of Investing In Structure Therapeutics Inc ADR (GPCR) - knoxdaily.com
How should investors view Nano X Imaging Ltd (NNOX)? - uspostnews.com
Complete Solaria Inc (CSLR) produces promising results - uspostnews.com
Buy Rating for Structure Therapeutics: Aleniglipron’s Competitive Edge in the Oral GLP-1 Market - TipRanks
Russell Investments Group Ltd. Purchases 2,888 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Average Target Price from Brokerages - Defense World
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study - Zacks Investment Research
What Are You Thinking About Investing In Structure Therapeutics Inc ADR (NASDAQ: GPCR) Stock? - Stocksregister
Analysts’ Top Healthcare Picks: Evolent Health (EVH), Gilead Sciences (GILD) - The Globe and Mail
JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics - Yahoo Finance
Bank of Montreal Can Acquires 3,671 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - American Banking and Market News
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback - Zacks Investment Research
Structure Therapeutics Inc ADR (NASDAQ: GPCR) Stock: A Value Hunter’s Investment? - stocksregister.com
Structure Therapeutics shares rise on Pfizer’s obesity drug exit By Investing.com - Investing.com Canada
Structure Therapeutics shares rise on Pfizer’s obesity drug exit - Investing.com
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today - The Motley Fool
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Praxis Precision Medicines (PRAX) - The Globe and Mail
What is Iterum Therapeutics Plc (ITRM) Stock Return on Shareholders’ Capital? - Sete News
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail
Cognito Therapeutics Announces Spectris™ Data Demonstrating Brain Structural Maintenance and Mechanism of Action in Alzheimer’s Disease at AD/PD™ 2025 - Business Wire
Predicting Upstart Holdings Inc’s (UPST) earnings for the current quarter - uspostnews.com
GPCR stock touches 52-week low at $19.29 amid market challenges - Investing.com Canada
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - Defense World
Cognito Therapeutics to Present New Data on Spectris’™ Impact on Brain Structure in Alzheimer’s Disease at AD/PD 2025 - Business Wire
Structure Therapeutics CEO on latest GLP-1 developments - CNBC
Oral Proteins and Peptides Market Know the Scope and Trends As Revealed In New Report - WhaTech
A new biotech licensing Chinese drugs with a unique approach gets high-profile backing - statnews.com
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Xoma (XOMA) - The Globe and Mail
Acute Bacterial Skin and Skin-Structure Infection Market - openPR
Jones Financial Companies Lllp Raises Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Assetmark Inc. - Defense World
Analysts Update Their Estimates For Structure Therapeutics Inc ADR - Stocks Register
GPCR Stock Hits 52-Week Low at $19.61 Amid Market Challenges - Investing.com Canada
Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics - Nature.com
Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality - The Globe and Mail
Structure Therapeutics (GPCR) Projected to Post Quarterly Earnings on Friday - Defense World
Research Analysts Issue Forecasts for GPCR Q4 Earnings - Defense World
Q1 Earnings Estimate for GPCR Issued By Leerink Partnrs - Defense World
Structure Therapeutics, Inc.: Strong Pipeline and Financial Stability Underpin Buy Rating Despite Price Target Reduction - TipRanks
Structure Therapeutics Inc ADR’s (NASDAQ: GPCR) Stock Price Continues To Fall - Stocks Register
Leerink cuts Structure Therapeutics target to $60, keeps outperform - Investing.com India
Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at William Blair - Defense World
Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29 - Defense World
Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at William Blair - MarketBeat
Structure Therapeutics Advances in Obesity Treatment Pipeline - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 8% on Earnings Beat - MarketBeat
Structure Therapeutics, Inc.: Promising Outlook with Aleniglipron in Obesity Treatment and Strategic Advancements Justify Buy Rating - TipRanks
Promising Potential of Structure Therapeutics’ Aleniglipron: A Compelling Buy Recommendation - TipRanks
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):